Clinical Trial Details


Back to Clinical Trials Database

A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma (HGUtS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment

Study documentation Publications

Trial Status Recruiting
Dates Date of activation: 30-Jan-2015
Data management at EORTC Yes
Design Phase 2
Randomized blind
Targeted Sample size EORTC Groups: 50 - All Groups: 78
Treatment Drug
Cabozantinib, Blind trial medication-62113
Study Staff Isabelle Ray Coquard (Study Coordinator) , Centre Leon Berard, Lyon
Maarten Caspers (Data Manager) , EORTC Headquarters, Brussels
Kin Jip Cheung (Unblinded COM) , EORTC Headquarters, Brussels
Corneel Coens (Statistician) , EORTC Headquarters, Brussels
Laura De Meulemeester (Unblinded COM) , EORTC Headquarters, Brussels
Catherine Fortpied (Unblinded statistician) , EORTC Headquarters, Brussels
Stephanie Kromar (Regulatory Affairs Manager) , EORTC Headquarters, Brussels
Fiona Namanya (Clinical Operations Assistant) , EORTC Headquarters, Brussels
Bette Stofs (Pharmacovigilance Manager) , EORTC Headquarters, Brussels
Maureen Vanlancker (Clinical Research Physician) , EORTC Headquarters, Brussels
Christophe Verstegen (Clinical Operations Manager) , EORTC Headquarters, Brussels
Xiao Mang Zhou (Regulatory Affairs Administrator) , EORTC Headquarters, Brussels
Type of cancer Uterine
Participating groups EORTC Gynecological Cancer Group
EORTC Soft Tissue and Bone Sarcoma Group
National Cancer Research Institute - Gyneco Cancer Group
National Cancer Research Institute - Sarcoma Group
Gynaecological Oncology Group
Recruiting centers Amsterdam UMC - Locatie AMC (Amsterdam, Netherlands)
Cambridge University Hospital NHS - Addenbrookes Hospital (Cambridge, United Kingdom)
Centre Georges-Francois-Leclerc (Dijon, France)
Centre Leon Berard (Lyon, France)
Hospital Universitario San Carlos (Madrid, Spain)
IRCCS - Istituto Nazionale dei Tumori (Milano, Italy)
Institut Bergonie (Bordeaux, France)
Institut de Cancerologie de l’Ouest (ICO) - Centre Rene Gauducheau (Nantes - St. Herblain, France)
Leeds Teaching Hospitals NHS Trust - St. James's University Hospital (Leeds, United Kingdom)
Ludwig-Maximilians-Universitaet Muenchen - Campus Grosshadern (Muenchen, Germany)
NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital (Glasgow, United Kingdom)
Nottingham University Hospitals NHS Trust - City Hospital (Nottingham, United Kingdom)
Oxford University Hospitals NHS Trust - Churchill Hospital (Oxford, United Kingdom)
Royal Marsden Hospital - Chelsea, London (London, United Kingdom)
Universitaetsklinikum Tuebingen-Uni Kliniken Berg (Tuebingen, Germany)
Universitair Ziekenhuis Antwerpen (Edegem, Belgium)
University College Hospital (London, United Kingdom)
Vall d'Hebron Institut Oncologia (Barcelona, Spain)
Protocol summary
NCT number NCT01979393
EudraCT 2013-000762-11
Financial Support EORTC Group